Compare RIO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIO | SNY |
|---|---|---|
| Founded | 1873 | 1994 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.3B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | RIO | SNY |
|---|---|---|
| Price | $96.37 | $48.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $85.00 | $61.50 |
| AVG Volume (30 Days) | ★ 4.9M | 3.8M |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | ★ 3.85% | 3.37% |
| EPS Growth | N/A | ★ 44.16 |
| EPS | 6.28 | ★ 7.52 |
| Revenue | $53,729,000,000.00 | ★ $54,850,299,422.00 |
| Revenue This Year | $7.31 | $2.70 |
| Revenue Next Year | $3.52 | $6.84 |
| P/E Ratio | $15.35 | ★ $12.62 |
| Revenue Growth | N/A | ★ 5.49 |
| 52 Week Low | $51.67 | $44.62 |
| 52 Week High | $97.11 | $60.12 |
| Indicator | RIO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 72.05 | 53.95 |
| Support Level | $89.63 | $47.20 |
| Resistance Level | $97.11 | $47.89 |
| Average True Range (ATR) | 2.01 | 0.73 |
| MACD | 0.42 | 0.17 |
| Stochastic Oscillator | 85.86 | 83.58 |
Rio Tinto is a global diversified miner. Iron ore is the dominant commodity, with significantly lesser contributions from copper, aluminum, diamonds, gold, and industrial minerals. The 1995 merger of RTZ and CRA, via a dual-listed structure, created the present-day company. The two operate as a single business entity, with shareholders in each company having equivalent economic and voting rights. Major assets included the Pilbara iron ore operations, a 30% stake in the Escondida copper mine, 66%-ownership of the Oyu Tolgoi copper mine in Mongolia, the Weipa and Gove bauxite mines in Australia, and six hydro-powered aluminum smelters in Canada.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.